Protective effect of the 20-HETE inhibitor HET0016 on brain damage after temporary focal ischemia

Samuel M. Poloyac, Yuqing Zhang, Robert R. Bies, Patrick M. Kochanek, Steven H. Graham

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Cytochrome P450 metabolism of arachidonic acid produces the potent vasoconstrictive metabolite, 20-hydroxyeicosatetraenoic acid (20-HETE). Recent studies have implicated 20-HETE as a vasoconstrictive mediator in hemorrhagic stroke. The purpose of this study was to determine the effect of the 20-HETE inhibitor, HET0016, on lesion volume and cerebral blood flow (CBF) after temporary middle cerebral artery occlusion (MCAO) in rats. Plasma pharmacokinetics and tissue concentrations of HET0016 were determined after a 10 mg/kg intraperitoneal dose. Separate rats were treated with HET0016 or vehicle before 90 mins of MCAO. Lesion volume was assessed by 2,3,5-triphenyl- tetrazolium-chloride and cerebral flow was determined using laser Doppler flow. The effect of MCAO on in vitro microsomal formation of mono-oxygenated arachidonic acid metabolites was also determined. Results show that HET0016 has a short biologic half-life, distributes into the brain, and is associated with a 79.6% reduction in 20-HETE concentration in the cortex. Lesion volume was greatly reduced in HET0016-treated (9.1%±4.9%) versus vehicle-treated (57.4%±9.8%; n=6; P<0.001) rats. An attenuation of the observed decrease in CBF was observed in HET0016-treated (180 mins 89.2%±6.2%; 240 mins 88.1%±5.7% of baseline flow) versus vehicle control (180 mins 57.6%±19.0% 240 mins 53.8%±20.0% of baseline flow; n=6; P<0.05). Brain cortical microsomal formation rate of 20-HETE was also reduced at 24 h in the ipsilateral hemisphere after MCAO. These data support a significant role for 20-HETE in the pathogenesis of ischemic stroke.

Original languageEnglish (US)
Pages (from-to)1551-1561
Number of pages11
JournalJournal of Cerebral Blood Flow and Metabolism
Volume26
Issue number12
DOIs
StatePublished - Dec 8 2006

Fingerprint

Ischemia
Middle Cerebral Artery Infarction
Cerebrovascular Circulation
Brain
Arachidonic Acid
Stroke
Cytochrome P-450 Enzyme System
Half-Life
20-hydroxy-5,8,11,14-eicosatetraenoic acid
Chlorides
Lasers
Pharmacokinetics

Keywords

  • Arachidonic acid
  • Cytochrome P450
  • Hydroxyeicosatetraenoic acid
  • Middle cerebral artery occlusion
  • N-hydroxy-N-4-butyl-2-methylphenylformamidine
  • Stroke

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Protective effect of the 20-HETE inhibitor HET0016 on brain damage after temporary focal ischemia. / Poloyac, Samuel M.; Zhang, Yuqing; Bies, Robert R.; Kochanek, Patrick M.; Graham, Steven H.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 26, No. 12, 08.12.2006, p. 1551-1561.

Research output: Contribution to journalArticle

Poloyac, Samuel M. ; Zhang, Yuqing ; Bies, Robert R. ; Kochanek, Patrick M. ; Graham, Steven H. / Protective effect of the 20-HETE inhibitor HET0016 on brain damage after temporary focal ischemia. In: Journal of Cerebral Blood Flow and Metabolism. 2006 ; Vol. 26, No. 12. pp. 1551-1561.
@article{74e51c14402446a9a774a3d5229d2ae6,
title = "Protective effect of the 20-HETE inhibitor HET0016 on brain damage after temporary focal ischemia",
abstract = "Cytochrome P450 metabolism of arachidonic acid produces the potent vasoconstrictive metabolite, 20-hydroxyeicosatetraenoic acid (20-HETE). Recent studies have implicated 20-HETE as a vasoconstrictive mediator in hemorrhagic stroke. The purpose of this study was to determine the effect of the 20-HETE inhibitor, HET0016, on lesion volume and cerebral blood flow (CBF) after temporary middle cerebral artery occlusion (MCAO) in rats. Plasma pharmacokinetics and tissue concentrations of HET0016 were determined after a 10 mg/kg intraperitoneal dose. Separate rats were treated with HET0016 or vehicle before 90 mins of MCAO. Lesion volume was assessed by 2,3,5-triphenyl- tetrazolium-chloride and cerebral flow was determined using laser Doppler flow. The effect of MCAO on in vitro microsomal formation of mono-oxygenated arachidonic acid metabolites was also determined. Results show that HET0016 has a short biologic half-life, distributes into the brain, and is associated with a 79.6{\%} reduction in 20-HETE concentration in the cortex. Lesion volume was greatly reduced in HET0016-treated (9.1{\%}±4.9{\%}) versus vehicle-treated (57.4{\%}±9.8{\%}; n=6; P<0.001) rats. An attenuation of the observed decrease in CBF was observed in HET0016-treated (180 mins 89.2{\%}±6.2{\%}; 240 mins 88.1{\%}±5.7{\%} of baseline flow) versus vehicle control (180 mins 57.6{\%}±19.0{\%} 240 mins 53.8{\%}±20.0{\%} of baseline flow; n=6; P<0.05). Brain cortical microsomal formation rate of 20-HETE was also reduced at 24 h in the ipsilateral hemisphere after MCAO. These data support a significant role for 20-HETE in the pathogenesis of ischemic stroke.",
keywords = "Arachidonic acid, Cytochrome P450, Hydroxyeicosatetraenoic acid, Middle cerebral artery occlusion, N-hydroxy-N-4-butyl-2-methylphenylformamidine, Stroke",
author = "Poloyac, {Samuel M.} and Yuqing Zhang and Bies, {Robert R.} and Kochanek, {Patrick M.} and Graham, {Steven H.}",
year = "2006",
month = "12",
day = "8",
doi = "10.1038/sj.jcbfm.9600309",
language = "English (US)",
volume = "26",
pages = "1551--1561",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Protective effect of the 20-HETE inhibitor HET0016 on brain damage after temporary focal ischemia

AU - Poloyac, Samuel M.

AU - Zhang, Yuqing

AU - Bies, Robert R.

AU - Kochanek, Patrick M.

AU - Graham, Steven H.

PY - 2006/12/8

Y1 - 2006/12/8

N2 - Cytochrome P450 metabolism of arachidonic acid produces the potent vasoconstrictive metabolite, 20-hydroxyeicosatetraenoic acid (20-HETE). Recent studies have implicated 20-HETE as a vasoconstrictive mediator in hemorrhagic stroke. The purpose of this study was to determine the effect of the 20-HETE inhibitor, HET0016, on lesion volume and cerebral blood flow (CBF) after temporary middle cerebral artery occlusion (MCAO) in rats. Plasma pharmacokinetics and tissue concentrations of HET0016 were determined after a 10 mg/kg intraperitoneal dose. Separate rats were treated with HET0016 or vehicle before 90 mins of MCAO. Lesion volume was assessed by 2,3,5-triphenyl- tetrazolium-chloride and cerebral flow was determined using laser Doppler flow. The effect of MCAO on in vitro microsomal formation of mono-oxygenated arachidonic acid metabolites was also determined. Results show that HET0016 has a short biologic half-life, distributes into the brain, and is associated with a 79.6% reduction in 20-HETE concentration in the cortex. Lesion volume was greatly reduced in HET0016-treated (9.1%±4.9%) versus vehicle-treated (57.4%±9.8%; n=6; P<0.001) rats. An attenuation of the observed decrease in CBF was observed in HET0016-treated (180 mins 89.2%±6.2%; 240 mins 88.1%±5.7% of baseline flow) versus vehicle control (180 mins 57.6%±19.0% 240 mins 53.8%±20.0% of baseline flow; n=6; P<0.05). Brain cortical microsomal formation rate of 20-HETE was also reduced at 24 h in the ipsilateral hemisphere after MCAO. These data support a significant role for 20-HETE in the pathogenesis of ischemic stroke.

AB - Cytochrome P450 metabolism of arachidonic acid produces the potent vasoconstrictive metabolite, 20-hydroxyeicosatetraenoic acid (20-HETE). Recent studies have implicated 20-HETE as a vasoconstrictive mediator in hemorrhagic stroke. The purpose of this study was to determine the effect of the 20-HETE inhibitor, HET0016, on lesion volume and cerebral blood flow (CBF) after temporary middle cerebral artery occlusion (MCAO) in rats. Plasma pharmacokinetics and tissue concentrations of HET0016 were determined after a 10 mg/kg intraperitoneal dose. Separate rats were treated with HET0016 or vehicle before 90 mins of MCAO. Lesion volume was assessed by 2,3,5-triphenyl- tetrazolium-chloride and cerebral flow was determined using laser Doppler flow. The effect of MCAO on in vitro microsomal formation of mono-oxygenated arachidonic acid metabolites was also determined. Results show that HET0016 has a short biologic half-life, distributes into the brain, and is associated with a 79.6% reduction in 20-HETE concentration in the cortex. Lesion volume was greatly reduced in HET0016-treated (9.1%±4.9%) versus vehicle-treated (57.4%±9.8%; n=6; P<0.001) rats. An attenuation of the observed decrease in CBF was observed in HET0016-treated (180 mins 89.2%±6.2%; 240 mins 88.1%±5.7% of baseline flow) versus vehicle control (180 mins 57.6%±19.0% 240 mins 53.8%±20.0% of baseline flow; n=6; P<0.05). Brain cortical microsomal formation rate of 20-HETE was also reduced at 24 h in the ipsilateral hemisphere after MCAO. These data support a significant role for 20-HETE in the pathogenesis of ischemic stroke.

KW - Arachidonic acid

KW - Cytochrome P450

KW - Hydroxyeicosatetraenoic acid

KW - Middle cerebral artery occlusion

KW - N-hydroxy-N-4-butyl-2-methylphenylformamidine

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=33751336305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751336305&partnerID=8YFLogxK

U2 - 10.1038/sj.jcbfm.9600309

DO - 10.1038/sj.jcbfm.9600309

M3 - Article

C2 - 16570075

AN - SCOPUS:33751336305

VL - 26

SP - 1551

EP - 1561

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 12

ER -